A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer

J. Lickliter, Hui K. Gan, B. Gao, P. Grimison, J. Zou, H. Kallender, K. Sun, X. Chen, A. Behren, P. Fernandez-Penas, A. Nagrial, M. Voskoboynik, K. Woods, M. Millward, T. Meniawy

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume28
Publication statusPublished - Sep 2017
Externally publishedYes
Event42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain
Duration: 8 Sep 201712 Sep 2017

Cite this

Lickliter, J., Gan, H. K., Gao, B., Grimison, P., Zou, J., Kallender, H., Sun, K., Chen, X., Behren, A., Fernandez-Penas, P., Nagrial, A., Voskoboynik, M., Woods, K., Millward, M., & Meniawy, T. (2017). A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer. Annals of Oncology, 28.